Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Gastroenterology

• Publication date

  2014-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1053/j.gastro.2014.08.031PMID 25450083
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis

  2014cited by this paper
• Effects of the adjunctive probiotic VSL#3 on portal haemodynamics in patients with cirrhosis and large varices: a randomized trial

  2013cited by this paper
• Correlation between degree and quality of sleep disturbance and the level of neuropsychiatric impairment in patients with liver cirrhosis

  2013cited by this paper
• Systemic inflammation and ammonia in hepatic encephalopathy

  2013cited by this paper
• The nutritional management of hepatic encephalopathy in patients with cirrhosis: International society for hepatic encephalopathy and nitrogen metabolism consensus

  2013cited by this paper
• Gut microbiota and hepatic encephalopathy

  2013cited by this paper
• Linkage of gut microbiome with cognition in hepatic encephalopathy.

  2012cited by this paper
• Probiotic Bacteria Regulate Intestinal Epithelial Permeability in Experimental Ileitis by a TNF-Dependent Mechanism

  2012cited by this paper
• Probiotics for patients with hepatic encephalopathy.

  2011cited by this paper
• Pathogenesis, diagnosis, and treatment of hepatic encephalopathy.

  2011cited by this paper
• Gut Microbiota and Inflammation

  2011cited by this paper
• Infection and systemic inflammation, not ammonia, are associated with Grade 3/4 hepatic encephalopathy, but not mortality in cirrhosis.

  2011cited by this paper
• Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis: An Open-Label, Randomized Controlled Trial of Lactulose, Probiotics, and No Therapy

  2010cited by this paper
• Clinical course of alcoholic liver cirrhosis: A Danish population‐based cohort study

  2010cited by this paper
• Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy.

  2010cited by this paper
• Diagnosis and Prognostic Significance of Minimal Hepatic Encephalopathy in Patients with Cirrhosis of Liver

  2010cited by this paper
• Factors Affecting Compliance and Persistence with Treatment for Hepatic Encephalopathy

  2010cited by this paper
• Rifaximin treatment in hepatic encephalopathy.

  2010cited by this paper
• Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo.

  2009cited by this paper
• Probiotics promote gut health through stimulation of epithelial innate immunity

  2009cited by this paper
• Brain natriuretic peptide in decompensation of liver cirrhosis in non-cardiac patients.

  2009cited by this paper
• Management of adult patients with ascites due to cirrhosis: An update

  2009cited by this paper
• Probiotic Yogurt for the Treatment of Minimal Hepatic Encephalopathy

  2008cited by this paper
• Hepatic encephalopathy as a predictor of survival in patients with end‐stage liver disease

  2007cited by this paper
• Review article: the burden of hepatic encephalopathy

  2007cited by this paper
• Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis

  2007cited by this paper
• [Effect of administration of Escherichia coli Nissle (Mutaflor) on intestinal colonisation, endo-toxemia, liver function and minimal hepatic encephalopathy in patients with liver cirrhosis].

  2006cited by this paper
• Effect of lactulose and Saccharomyces boulardii administration on the colonic urea‐nitrogen metabolism and the bifidobacteria concentration in healthy human subjects

  2006cited by this paper
• Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials

  2004cited by this paper
• Synbiotic modulation of gut flora: Effect on minimal hepatic encephalopathy in patients with cirrhosis

  2004cited by this paper
• Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis.

  2004cited by this paper
• Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease

  2003cited by this paper
• Influence of Hepatic Encephalopathy on Health-Related Quality of Life in Patients with Cirrhosis

  2003cited by this paper
• Hepatic encephalopathy—Definition, nomenclature, diagnosis, and quantification: Final report of the Working Party at the 11th World Congresses of Gastroenterology, Vienna, 1998

  2002cited by this paper
• Prognostic significance of hepatic encephalopathy in patients with cirrhosis.

  1999cited by this paper
• Figure connection test: A universal test for assessment of mental state

  1995cited by this paper
• A new method for measuring daytime sleepiness: the Epworth sleepiness scale.

  1991cited by this paper
• The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research.

  1989cited by this paper
• Serum indole and skatole in patients with various liver diseases.

  1988cited by this paper

• Probiotics for managing non-alcoholic fatty liver disease: efficacy and mechanistic insights

  2026cites this paper
• ACG Clinical Guideline: Hepatic Encephalopathy.

  2026cites this paper
• A multi-strain probiotic modulates gut microbiome composition, intestinal barrier integrity and inflammation in a multi-compartmental in vitro gut model of decompensated alcohol-related advanced chronic liver disease.

  2026cites this paper
• Gut microbiome in biliary atresia

  2026cites this paper
• Gut Microbiota and the Gut–Liver Axis in Liver Disease: From Chronic Viral Hepatitis to Cirrhosis, Hepatocellular Carcinoma, and Microbiome-Based Therapies

  2025cites this paper
• A Lactobacillus consortium provides insights into the sleep-exercise-microbiome nexus in proof of concept studies of elite athletes and in the general population

  2025cites this paper
• The Gut‒Liver Axis in Liver Disease: Molecular Mechanisms and Therapeutic Targets

  2025cites this paper
• Fecal Butyrate and Deoxycholic Acid Concentrations Correlate With Mortality in Patients With Liver Disease

  2025cites this paper
• Microbial Approaches to Treat and Prevent Hepatic Encephalopathy.

  2025cites this paper
• Management of hepatic encephalopathy following transjugular intrahepatic portosystemic shunts: Current strategies and future directions

  2025cites this paper
• The role of gut microbiota in modulating immune responses in chronic liver disease: a systematic review and meta-analysis

  2025cites this paper
• Synbiotic administration improves systemic and vascular alterations in rats with experimental microsurgical extrahepatic cholestasis: role of perivascular mesenteric innervation

  2025cites this paper
• Effects of Lactobacillus sporogenesis on Pediatric Cholestatic Liver Disease: A Randomized, Triple-Blind, Placebo-Controlled Trial

  2025cites this paper
• Hepatic encephalopathy in cirrhosis: therapies and developments

  2025cites this paper
• Efficacies of Bifidobacterium and Fecal Microbiota Transplantation in Rats With Chronic Hepatic Encephalopathy Assessed by [18F]PBR146 Imaging of Neuroinflammation

  2025cites this paper
• Can the use of synbiotics following live donor liver transplantation alter the microbiota milieu, decrease infection rates and improve graft survival?

  2025cites this paper
• Microbiota in Alcohol-Associated Organ Damage.

  2025cites this paper
• Therapeutic manipulation of the microbiome in liver disease.

  2024cites this paper
• Insights of gut-liver axis in hepatic diseases: Mechanisms, clinical implications, and therapeutic potentials

  2024cites this paper
• Effects of Probiotics on Liver Diseases: Current In Vitro and In Vivo Studies

  2024cites this paper
• Components from Curcuma longa (Turmeric) Against Hepatobiliary Diseases Based on Gut-Liver Axis: Pharmacotherapeutic Properties and Potential Clinical Applications.

  2024cites this paper
• Effect of intestinal microbiota transplantation on chronic hepatitis B virus infection associated liver disease

  2024cites this paper
• Biomarkers of Frailty in Patients with Advanced Chronic Liver Disease Undergoing a Multifactorial Intervention Consisting of Home Exercise, Branched-Chain Amino Acids, and Probiotics

  2024cites this paper
• Probiotics—A Promising Novel Therapeutic Approach in the Management of Chronic Liver Diseases

  2024cites this paper
• The Effects of Adding Probiotic, Alone and in Combination With Zinc, to Routine Treatment on Recurrence of Hepatic Encephalopathy, Quality of Life, and Sleep Quality in Patients With Cirrhosis: An Open‐Label Randomized Controlled Trial

  2024cites this paper
• Influence of the gut microbiota on immune cell interactions and cancer treatment

  2024cites this paper
• Hyperammonemia in adults - 2025. Practical recommendations

  2024cites this paper
• Chinese consensus on the management of liver cirrhosis

  2024cites this paper
• Gut microbiota dysbiosis mediates mouse kidney fibrosis induced by black phosphorus quantum dots

  2024cites this paper
• Efficacy of Probiotics on Improvement of Health Outcomes in Cirrhotic Liver Disease Patients: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.

  2024cites this paper
• Survival and cancer recurrence after short-course perioperative probiotics in a randomized trial.

  2024cites this paper
• Multi-omics approaches to studying gastrointestinal microbiome in the context of precision medicine and machine learning

  2024cites this paper
• Current Management of Hepatic Encephalopathy

  2024cites this paper
• Probiotics are beneficial for liver cirrhosis: a systematic review and meta-analysis of randomized control trials

  2024cites this paper
• Gut Bacteria in Alcohol-Associated Liver Disease.

  2024cites this paper
• Prophylaxis of hepatic encephalopathy: current and future drug targets

  2024cites this paper
• Home exercise, branched-chain amino acids, and probiotics improve frailty in cirrhosis: A randomized clinical trial

  2024cites this paper
• Microbiota and Gut–Liver Axis: An Unbreakable Bond?

  2024cites this paper
• Gut Microbiome and Cancer: From Cancer Development to Therapeutics with a Special Focus on Hepatocellular Carcinoma.

  2024cites this paper
• Present and future of fecal microbiome transplantation in cirrhosis.

  2024cites this paper
• LACTOBACILLI SPECIES’ EFFECTS ON LIVER FUNCTION: A REVIEW

  2023cites this paper
• The Intestinal Microbiota in the Development of Chronic Liver Disease: Current Status

  2023cites this paper
• Nutritional intervention is promising in alleviating liver injury during tuberculosis treatment: a review

  2023cites this paper
• Bifidobacteria metabolize lactulose to optimize gut metabolites and prevent systemic infection in patients with liver disease

  2023cites this paper
• Do gut microbiome‐targeted therapies improve liver function in cirrhotic patients? A systematic review and meta‐analysis

  2023influential citation
• Alterations in the gut microbiota and the efficacy of adjuvant probiotic therapy in liver cirrhosis

  2023cites this paper
• Effect of probiotics on nutritional status, biochemical parameters, and disease severity in cirrhotic patients referred for liver transplantation-A randomised double blind, placebo-controlled trial.

  2023cites this paper
• Harnessing the potential of probiotics in the treatment of alcoholic liver disorders

  2023cites this paper
• Drinking and laboratory biomarkers, and nutritional status characterize the clinical presentation of early-stage alcohol-associated liver disease.

  2023cites this paper
• Gut Microbiota and Neuroinflammation in Acute Liver Failure and Chronic Liver Disease

  2023cites this paper
• Probiotic management and inflammatory factors as a novel treatment in cirrhosis: A systematic review and meta-analysis

  2023cites this paper
• Role of Probiotics in Secondary Prophylaxis of Hepatic Encephalopathy

  2023cites this paper
• Nutritional therapy for persistent cognitive impairment after resolution of overt hepatic encephalopathy in patients with cirrhosis: A double‐blind randomized controlled trial

  2023cites this paper
• A meta-analysis of microbiome therapies for hepatic encephalopathy

  2023cites this paper
• Comparison of the effects of probiotics, rifaximin, and lactulose in the treatment of minimal hepatic encephalopathy and gut microbiota

  2023cites this paper
• Potential therapies for acute‐on‐chronic liver failure

  2023cites this paper
• Update in the treatment of the complications of cirrhosis.

  2023cites this paper
• State of the art in research on the gut-liver and gut-brain axis in poultry

  2023cites this paper
• Sarcopenia in cirrhosis: Prospects for therapy targeted to gut microbiota

  2023cites this paper
• A REVIEW OF THE PHYTOCHEMICAL PROPERTIES AND PHARMACOLOGICAL USES OF THE GENUS PISTACIA L. (ANACARDIACEAE)

  2023influential citation
• The Role of the Gut Microbiome and Trimethylamine Oxide in Atherosclerosis and Age-Related Disease

  2023cites this paper
• The human-derived novel gut commensal Luoshenia tenuis regulates body weight and food intake in mice

  2023cites this paper
• Association between probiotic therapy and the risk of hepatocellular carcinoma in patients with hepatitis B-related cirrhosis

  2023cites this paper
• Prebiotic activity of lactulose optimizes gut metabolites and prevents systemic infection in liver disease patients

  2023cites this paper
• Microbiota Composition and Probiotics Supplementations on Sleep Quality—A Systematic Review and Meta-Analysis

  2023cites this paper
• Hepatic encephalopathy: From novel pathogenesis mechanism to emerging treatments

  2023cites this paper
• Cholestasis: exploring the triangular relationship of gut microbiota-bile acid-cholestasis and the potential probiotic strategies

  2023cites this paper
• Gut Microbiota Modulation: A Viable Strategy to Address Medical Needs in Hepatocellular Carcinoma and Liver Transplantation

  2023cites this paper
• Roles of human gut microbiota in liver cirrhosis risk: a two-sample mendelian randomization study.

  2023cites this paper
• A Comprehensive Overview of the Past, Current, and Future Randomized Controlled Trials in Hepatic Encephalopathy

  2023cites this paper
• Effect of intestinal microbiota on liver disease and its related future prospection: From the perspective of intestinal barrier damage and microbial metabolites

  2023cites this paper
• Hepatic encephalopathy – recent advances in treatment and diagnosis

  2023cites this paper
• Intestinal dysbiosis and probiotic use: its place in hepatic encephalopathy in cirrhosis

  2023influential citation
• Circadian Rhythms Coordinated With Gut Microbiota Partially Account for Individual Differences in Hepatitis B-Related Cirrhosis

  2022cites this paper
• Influences of Oral Administration of Probiotics on Posthepatectomy Recovery in Patients in Child-Pugh Grade

  2022cites this paper
• Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases

  2022cites this paper
• Hepatic encephalopathy

  2022cites this paper
• Hepatocellular carcinoma and microbiota: Implications for clinical management and treatment

  2022cites this paper
• Overview of Complications in Cirrhosis.

  2022cites this paper
• Promises of microbiome-based therapies.

  2022cites this paper
• Trust Your Gut: The Association of Gut Microbiota and Liver Disease

  2022cites this paper
• The Link between Gut Microbiota and Hepatic Encephalopathy

  2022cites this paper
• Gut Microbiota Targeted Approach in the Management of Chronic Liver Diseases

  2022cites this paper
• Novel Drugs for the Management of Hepatic Encephalopathy: Still a Long Journey to Travel.

  2022cites this paper
• Russian Consensus on “Hyperammonemia in Adults”: The 2021 Version (in English)

  2022cites this paper
• Fatty liver and risk of dementia NAFLD increases a risk of stroke DPP-4 inhibitor-specific biomarkers in NAFLD LPS promotes HCC by NETs formation via TLR4 CLIF-SOFA score and sepsis

  2022cites this paper
• Fecal microbiota transplantation in alcohol-associated acute-on-chronic liver failure: an open-label clinical trial

  2022cites this paper
• A double blind randomized controlled trial to assess efficacy of nutritional therapy for prevention of recurrence of hepatic encephalopathy in patients with cirrhosis

  2022cites this paper
• Alterations of gut microbiome and effects of probiotic therapy in patients with liver cirrhosis: A systematic review and meta-analysis

  2022cites this paper
• The Effect of Heat-Killed Lactobacillus plantarum on Oxidative Stress and Liver Damage in Rats with Bile Duct Ligation-Induced Hepatic Fibrosis.

  2022cites this paper
• Response of Aedes aegypti (L.) Larvae to Seed-Derived Essential Oil and Seed-Derived Extract of Moringa oleifera (Lam.) International Journal of Zoological Investigations

  2022cites this paper
• Updates in the Role of Pre- and Probiotics in Health and Disease: Where Do We Stand Today?

  2022cites this paper
• Des probiotiques pour l’encéphalopathie hépatique

  2022cites this paper
• Microbial diversity associated with Tibetan kefir grains and its protective effects against ethanol-induced oxidative stress in HepG2 cells

  2022cites this paper
• Editorial: Manipulation of gut microbiota as a key target to intervene on the onset and progression of digestive system diseases

  2022cites this paper
• Microbiome Therapeutics for Hepatic Encephalopathy.

  2021cites this paper
• Associations of the gut microbiome with hepatic adiposity in the Multiethnic Cohort Adiposity Phenotype Study

  2021cites this paper
• Probiotics improve the neurometabolic profile of rats with chronic cholestatic liver disease

  2021cites this paper
• Therapeutic Applications of Resveratrol in Hepatic Encephalopathy through Its Regulation of the Microbiota, Brain Edema, and Inflammation

  2021cites this paper
• Intestinal microecology: A crucial strategy for targeted therapy of liver diseases.

  2021cites this paper